NDAINTRAVENOUSSOLUTION
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
AKOVAZ (ephedrine sulfate) by Dr. Reddy's Laboratories is α- and β-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Approved for allergic rhinitis. First approved in 2016.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKOVAZ (ephedrine sulfate) is an IV solution sympathomimetic agent that activates α- and β-adrenergic receptors while indirectly releasing norepinephrine from sympathetic neurons to increase arterial pressure, cardiac output, and peripheral resistance. It is approved for allergic rhinitis treatment via intravenous administration. The drug is a conventional small-molecule adrenergic agonist with a well-established mechanism dating back decades.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30/100), indicating mature commercial phase with stable demand but limited growth opportunity for expansion roles.
Mechanism of Action
α- and β-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic…
Indications (1)
Clinical Trials (1)
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
Started Apr 2006
34 enrolled
Healthy
Career Relevance
AKOVAZ is a niche acute-care IV product at peak lifecycle with no linked job openings, indicating a small, stable commercial footprint managed by a lean team. Career opportunities are limited to maintenance-focused roles in hospital sales, market access, and medical affairs rather than growth-oriented positions.
Worked on AKOVAZ at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.